239 related articles for article (PubMed ID: 15288314)
21. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
22. [The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].
Sun ST; Chen ZJ; Xu J; Tian XL
Zhonghua Yan Ke Za Zhi; 2006 Nov; 42(11):989-91. PubMed ID: 17386136
[TBL] [Abstract][Full Text] [Related]
23. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.
Noguchi N; Okihara T; Namiki Y; Kumaki Y; Yamanaka Y; Koyama M; Wakasugi K; Sasatsu M
Int J Antimicrob Agents; 2005 May; 25(5):374-9. PubMed ID: 15848290
[TBL] [Abstract][Full Text] [Related]
24. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
26. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
28. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Homma T; Hori T; Sugimori G; Yamano Y
Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
[TBL] [Abstract][Full Text] [Related]
30. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
31. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
33. The mutant selection window in rabbits infected with Staphylococcus aureus.
Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.
Campion JJ; Chung P; McNamara PJ; Titlow WB; Evans ME
Antimicrob Agents Chemother; 2005 Jun; 49(6):2189-99. PubMed ID: 15917512
[TBL] [Abstract][Full Text] [Related]
35. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
37. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
38. Determination of the mutant selection window for clindamycin, doxycycline, linezolid, moxifloxacin and trimethoprim/sulfamethoxazole against community-associated meticillin-resistant Staphylococcus aureus (MRSA).
Allen GP; Deshpande LM
Int J Antimicrob Agents; 2010 Jan; 35(1):45-9. PubMed ID: 19910164
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration.
Rodríguez JC; Cebrián L; López M; Ruiz M; Royo G
Int J Antimicrob Agents; 2005 Mar; 25(3):221-5. PubMed ID: 15737516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]